These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26065529)

  • 1. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
    Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIBF 1120 for the treatment of non-small cell lung cancer.
    Reck M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
    Girard N
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging angiogenesis inhibitors for non-small cell lung cancer.
    Malapelle U; Rossi A
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
    [No Abstract]   [Full Text] [Related]  

  • 5. [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
    Swidzińska E; Naumnik W; Chyczewska E
    Pneumonol Alergol Pol; 2006; 74(4):414-20. PubMed ID: 17427152
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
    Wei XW; Zhang ZR; Wei YQ
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
    Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
    Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S50. PubMed ID: 21884998
    [No Abstract]   [Full Text] [Related]  

  • 14. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].
    Hirai F
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):940-3. PubMed ID: 26353391
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor vasculature as a therapeutic target in non-small cell lung cancer.
    Bar J; Goss GD
    J Thorac Oncol; 2012 Mar; 7(3):609-20. PubMed ID: 22307008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
    Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
    Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenic agents of lung cancer].
    Wakuda K; Takahashi T
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):162-71. PubMed ID: 24743195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic agents.
    Stani SC; Capaccetti B; Bonginelli P; Sarmiento R; De Sio L; Fanelli M; Gasparini G
    Suppl Tumori; 2002; 1(4):S39-43. PubMed ID: 12415816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.